Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Profitability
This table compares Adial Pharmaceuticals and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adial Pharmaceuticals | N/A | -1,284.64% | -987.47% |
| Journey Medical | -8.95% | -20.23% | -6.60% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Adial Pharmaceuticals and Journey Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adial Pharmaceuticals | 1 | 2 | 3 | 0 | 2.33 |
| Journey Medical | 1 | 1 | 2 | 0 | 2.25 |
Risk & Volatility
Adial Pharmaceuticals has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
Institutional and Insider Ownership
16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Journey Medical shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Adial Pharmaceuticals and Journey Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adial Pharmaceuticals | N/A | N/A | -$7.98 million | ($7.98) | -0.63 |
| Journey Medical | $61.86 million | 2.90 | -$11.43 million | ($0.22) | -29.64 |
Adial Pharmaceuticals has higher earnings, but lower revenue than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Adial Pharmaceuticals beats Journey Medical on 8 of the 13 factors compared between the two stocks.
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
